KBC Zagreb
- Address
- lock Available on a paid plan
KBC Zagreb - Advanced Clinical Research Center
KBC Zagreb is a comprehensive medical research institution conducting cutting-edge clinical trials across multiple therapeutic areas. The center demonstrates particular expertise in neurological disorders, with extensive experience in multiple sclerosis research including relapsing-remitting, primary progressive, and relapsing forms of the disease. The institution actively investigates novel therapeutic approaches for neurodegenerative conditions such as Alzheimer's disease, including studies focused on cognitive impairment, psychosis, and agitation associated with dementia.
- Multiple Sclerosis and neuroinflammatory diseases (various disease-modifying therapies including biologics and small molecules)
- Oncology and hematologic malignancies (non-small cell lung cancer, lymphomas, leukemia, bladder cancer, and solid tumors)
- Inflammatory and autoimmune conditions (Crohn's disease, ulcerative colitis, hidradenitis suppurativa, bullous pemphigoid)
- Psychiatric and behavioral disorders (schizophrenia, bipolar disorder, major depressive disorder)
The research portfolio extends to rare diseases including spinal muscular atrophy and hemophilia with inhibitors, as well as cardiovascular disease prevention studies. KBC Zagreb participates in both early-phase dose-finding studies and large-scale Phase 3 pivotal trials, demonstrating capability in pharmacokinetic assessments, long-term safety extensions, and complex combination therapy protocols. The center's comprehensive approach encompasses emerging therapeutic modalities including CAR-T cell therapy, bispecific antibodies, and novel molecular targeted agents.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 21 therapeutic areas and 15 of 302 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 293 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 46 by active trials.
lock +45 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1AbbVie Deutschland GmbH & Co. KG15trials
lock +29 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 60 other sites in Croatia
Therapeutic Area Benchmark — Croatia
Select a therapeutic area to compare against other sites in Croatia.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Croatia
Market Share
Country: Croatia
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in KBC Zagreb
lock Showing 1 of 161 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Double-blind, Randomized, Active-controlled, Parallel-group, Phase 1/3 study to Compare Efficacy, Pharmacokinetics, Pharmacodynamics and Safety of CT-P53 and Ocrevus in Patients with Relapsing-remitting Multiple Sclerosis. | Celltrion Inc. | Phase III | Not Recruiting | Jan 2024 | — |
IMP list
lock Showing 1 of 302 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Pembrolizumab | 6 | Unknown | 2021-04-28 | 2025-06-12 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.